Artiva Biotherapeutics, Inc. Common Stock

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company developing natural killer (NK) cell-based therapies for autoimmune diseases and cancers. Its lead candidate, AlloNK, is an off-the-shelf NK cell therapy for conditions such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, pemphigus vulgaris, ANCA-associated vasculitis subtypes, and B-cell non-Hodgkin lymphoma. The company also develops AB-201, an allogeneic anti-HER2 CAR-NK candidate for solid tumors including breast, gastric, esophageal, and bladder cancers, and AB-205, an allogeneic anti-CD5 CAR-NK candidate for hematological malignancies. Incorporated in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.